AroCell AB (AROC) - Total Liabilities

Latest as of March 2025: Skr14.01 Million SEK ≈ $1.51 Million USD

Based on the latest financial reports, AroCell AB (AROC) has total liabilities worth Skr14.01 Million SEK (≈ $1.51 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of AroCell AB to assess how effectively this company generates cash.

AroCell AB - Total Liabilities Trend (2007–2024)

This chart illustrates how AroCell AB's total liabilities have evolved over time, based on quarterly financial data. See AroCell AB (AROC) shareholders funds for net asset value and shareholders' equity analysis.

AroCell AB Competitors by Total Liabilities

The table below lists competitors of AroCell AB ranked by their total liabilities.

Company Country Total Liabilities
Turk Ilac ve Serum Sanayi AS
IS:TRILC
Turkey TL4.21 Billion
Inepar S.A. Indústria e Construções
SA:INEP3
Brazil R$2.36 Billion
Sarama Resource
V:SWA
Canada CA$1.62 Million
VOGO SA
PA:ALVGO
France €12.66 Million
Tellusgruppen AB
ST:TELLUS
Sweden Skr89.49 Million
Future Retail Limited
NSE:FRETAIL
India Rs12.21 Billion
Indian Card Clothing Company Limited
NSE:INDIANCARD
India Rs288.15 Million
SAIHEAT Limited
NASDAQ:SAIH
USA $4.17 Million

Liability Composition Analysis (2007–2024)

This chart breaks down AroCell AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AroCell AB (AROC) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.69 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AroCell AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AroCell AB (2007–2024)

The table below shows the annual total liabilities of AroCell AB from 2007 to 2024.

Year Total Liabilities Change
2024-12-31 Skr12.93 Million
≈ $1.39 Million
+14.96%
2023-12-31 Skr11.25 Million
≈ $1.21 Million
-15.56%
2022-12-31 Skr13.32 Million
≈ $1.43 Million
+33.71%
2021-12-31 Skr9.96 Million
≈ $1.07 Million
+136.21%
2020-12-31 Skr4.22 Million
≈ $453.82K
-61.55%
2019-12-31 Skr10.97 Million
≈ $1.18 Million
+277.58%
2018-12-31 Skr2.90 Million
≈ $312.62K
+2.44%
2017-12-31 Skr2.84 Million
≈ $305.18K
-4.37%
2016-12-31 Skr2.97 Million
≈ $319.13K
+81.72%
2015-12-31 Skr1.63 Million
≈ $175.61K
-43.38%
2014-12-31 Skr2.88 Million
≈ $310.18K
+26.74%
2013-12-31 Skr2.27 Million
≈ $244.74K
+24.27%
2012-12-31 Skr1.83 Million
≈ $196.94K
-17.52%
2011-12-31 Skr2.22 Million
≈ $238.76K
-8.88%
2010-12-31 Skr2.43 Million
≈ $262.04K
-18.89%
2009-12-31 Skr3.00 Million
≈ $323.06K
+312.36%
2008-12-31 Skr728.00K
≈ $78.34K
+31.88%
2007-12-31 Skr552.00K
≈ $59.40K
--

About AroCell AB

ST:AROC Sweden Diagnostics & Research
Market Cap
$13.39 Million
Skr124.39 Million SEK
Market Cap Rank
#26150 Global
#556 in Sweden
Share Price
Skr0.54
Change (1 day)
+1.12%
52-Week Range
Skr0.50 - Skr0.60
All Time High
Skr15.05
About

AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more